Oncology and Hematology

Episodes 1-16 of 485

Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning
Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning
Project Oncology®
Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning
- Hallie Blevins, PhD.
Evolving Strategies in Resectable NSCLC: Insights from ASCO and ASTRO 2025
Evolving Strategies in Resectable NSCLC: Insights from ASCO and ASTRO 2025
Global Oncology Academy
Evolving Strategies in Resectable NSCLC: Insights from ASCO and ASTRO 2025
- Gerard A. Silvestri MD, MS, Master FCCP
- Jessica S. Donington, MD, MSCR
- Mariam Alexander, MD, PhD
- Anurag Singh, MD
Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
Project Oncology®
Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma
- Ryan Quigley
Optimizing Treatment Pathways in NSCLC: The Role of the Multidisciplinary Team
Optimizing Treatment Pathways in NSCLC: The Role of the Multidisciplinary Team
Global Oncology Academy
Optimizing Treatment Pathways in NSCLC: The Role of the Multidisciplinary Team
- Gerard A. Silvestri MD, MS, Master FCCP
- Jessica S. Donington, MD, MSCR
- Mariam Alexander, MD, PhD
- Anurag Singh, MD
Elacestrant and Targeted Therapies in Breast Cancer: Preliminary Data From ELECTRA and ELEVATE
Elacestrant and Targeted Therapies in Breast Cancer: Preliminary Data From ELECTRA and ELEVATE
Project Oncology®
Elacestrant and Targeted Therapies in Breast Cancer: Preliminary Data From ELECTRA and ELEVATE
- Jennifer Caudle, DO
- Hope S. Rugo, MD, FASCO
Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study
Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study
Project Oncology®
Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study
- Marlene Mimi Maeusli, PhD.
Exploring Elacestrant Combinations for ER+/HER2- mBC: Early Data from ELEVATE
Exploring Elacestrant Combinations for ER+/HER2- mBC: Early Data from ELEVATE
Project Oncology®
Exploring Elacestrant Combinations for ER+/HER2- mBC: Early Data from ELEVATE
- Charles Turck, PharmD, BCPS, BCCCP
- Virginia Kaklamani, MD
Expanding the Risk Profile: Genetic Insights Into Lung Cancer in Non-Smokers
Expanding the Risk Profile: Genetic Insights Into Lung Cancer in Non-Smokers
Project Oncology®
Expanding the Risk Profile: Genetic Insights Into Lung Cancer in Non-Smokers
- Paola Marignani, PhD, EMBA
CAR T and Bispecifics in LBCL: Redefining Second-Line Therapy Choices
CAR T and Bispecifics in LBCL: Redefining Second-Line Therapy Choices
Project Oncology®
CAR T and Bispecifics in LBCL: Redefining Second-Line Therapy Choices
- Charles Turck, PharmD, BCPS, BCCCP
- Samuel Yamshon, MD
CAR T in Marginal Zone Lymphoma: Insights from the TRANSCEND FL Study
CAR T in Marginal Zone Lymphoma: Insights from the TRANSCEND FL Study
Project Oncology®
CAR T in Marginal Zone Lymphoma: Insights from the TRANSCEND FL Study
- Charles Turck, PharmD, BCPS, BCCCP
- Sairah Ahmed, MD
Unlocking Tumor Complexity: Single-Cell RNA Sequencing in Lung Cancer
Unlocking Tumor Complexity: Single-Cell RNA Sequencing in Lung Cancer
Project Oncology®
Unlocking Tumor Complexity: Single-Cell RNA Sequencing in Lung Cancer
- Paola Marignani, PhD, EMBA
Refining Multimodal Therapy for Mesothelioma: Clinical Impact of SMART Sequencing
Refining Multimodal Therapy for Mesothelioma: Clinical Impact of SMART Sequencing
Project Oncology®
Refining Multimodal Therapy for Mesothelioma: Clinical Impact of SMART Sequencing
- John Cho, MD, PhD, FRCPC
From Policy to Practice: What the WHO Lung Health Resolution Means for Lung Cancer Care
From Policy to Practice: What the WHO Lung Health Resolution Means for Lung Cancer Care
Project Oncology®
From Policy to Practice: What the WHO Lung Health Resolution Means for Lung Cancer Care
- Ryan Quigley
CAR T and Bispecifics in LBCL: Redefining Second-Line Therapy Choices
CAR T and Bispecifics in LBCL: Redefining Second-Line Therapy Choices
Project Oncology®
CAR T and Bispecifics in LBCL: Redefining Second-Line Therapy Choices
- Charles Turck, PharmD, BCPS, BCCCP
- Samuel Yamshon, MD
The SMART Protocol in Mesothelioma: Challenges and Opportunities for Global Adoption
The SMART Protocol in Mesothelioma: Challenges and Opportunities for Global Adoption
Project Oncology®
The SMART Protocol in Mesothelioma: Challenges and Opportunities for Global Adoption
- John Cho, MD, PhD, FRCPC
Optimizing Outcomes in Endometrial Cancer: From Surgery to Recurrence Management
Optimizing Outcomes in Endometrial Cancer: From Surgery to Recurrence Management
Advances in Women's Health
Optimizing Outcomes in Endometrial Cancer: From Surgery to Recurrence Management
- Ann Klopp, M.D., Ph.D.